Author:
Eserian Jaqueline Kalleian,Lombardo Márcia
Abstract
Tablet splitting is a widespread practice among patients and health professionals aiming the administration of lower doses and the reduction of the cost of prescriptions. Nevertheless, potential concerns such as weight variation, stability and uneven drug content of the halves are related to this practice. The objective of this study was to evaluatethe uniformity of half-tablets regarding weight and drug content in three different commercial products containing propranolol. Also, it was assessed drug content for whole tablets. Weight variation and drug content uniformity tests were evaluated for whole and split tablets, as well as the weight loss due to the splitting process. Drug contentevaluation for whole tablets showed that all products were satisfactory. All the products were approved in the weight variation and drug content uniformity tests before splitting, with results close to 100%, but the halves of all products failed the tests, presenting a high variability between the portions. In one of the products, halves ranged from 75.5to 120.4% of the target drug content, indicating that when administered to patients, daily doses may vary around 45%. Splitting propranolol tablets might compromise clinical treatment, affecting blood pressure and consequently producing side effects. Clinical implications due to tablet splitting might not be critical in some cases. Nevertheless,the high variability between doses should be considered by healthcare professionals when prescribing a therapy involving this practice.
Publisher
Conselho Federal de Farmacia
Reference43 articles.
1. 1. Quinzler R, Gasse C, Schneider A, Kaufmann-Kolle P, Szecsenyi J, Haefeli WE. The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol. 2006; 62(12):1065-1073. DOI: 10.1007/s00228-006-0202-3
2. 2. Shah RB, Collier JS, Sayeed VA, Bryant A, Habib MJ, Khan MA. Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium. AAPS PharmSciTech. 2010; 11(3):1359-1367. DOI:10.1208/s12249-010-9515-8
3. 3. Gupta A, Hunt RL, Khan MA. Influence of tablet characteristics on weight variability and weight loss in split tablets. Am J Health Syst Pharm. 2008; 65(24):2326,2328. DOI:10.2146/ajhp080371
4. 4. van Vooren L, De Spiegeleer B, Thonissen T, Joye P, Van Durme J, Slegers G. Statistical analysis of Tablet breakability methods. J Pharm Pharm Sci. 2002; 5(2):190-198.
5. 5. Zhao N, Zidan A, Tawakkul M, Sayeed VA, Khan M. Tablet splitting: Product quality assessment of metoprolol succinate extended release tablets. Int J Pharm. 2010; 401(1-2):25-31. DOI: 10.1016/j.ijpharm.2010.09.004